AXSOME THERAPEUTICS SHARES GAIN 1.4% PREMARKET AFTER FDA GRANTS PRIORITY REVIEW FOR CO'S ALZHEIMER’S AGITATION DRUG

Reuters · 12/31/2025 12:25

Please log in to view news